35
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2018
Study Completion Date
February 18, 2019
ES414
ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
St. Vincent's Hospital Sydney, Darlinghurst
Peter MacCallum Cancer Centre, East Melbourne
Monash Medical Centre, Clayton
Roswell Park Cancer Institute, Buffalo
Central Texas Veterans Health Care System, Temple
University of California, San Francisco
University of Washington/Seattle Cancer Care Alliance, Seattle
Lead Sponsor
Aptevo Therapeutics
INDUSTRY